不丹引入肺炎球菌结合疫苗:确定最优政策方案的成本-效用分析
研究从不丹政府视角构建马尔可夫模型,比较10价与13价肺炎球菌结合疫苗(PCV10、PCV13)与不接种疫苗的成本-效用。结果显示,与不接种相比,PCV10和PCV13每获得1个质量调整生命年(QALY)的增量成本效果比分别为36美元和40美元,均低于人均GDP阈值2708美元,作者推荐将其纳入常规免疫规划。
要点
- 与不接种相比,PCV10和PCV13的ICER分别为36美元和40美元/QALY,均低于阈值2708美元。
- PCV13相比PCV10的ICER为92美元/QALY。
核心结论
- 在不丹人均GDP阈值2708美元下,PCV10和PCV13均具有成本效果,作者推荐将其纳入常规免疫规划。
研究设计与样本
- 研究采用政府视角的模型化成本-效用分析,使用一年周期长度的马尔可夫模拟模型,评估终身 horizon 内PCV10、PCV13和不接种三个方案的成本与结局。
- 贴现率设为每年3%,结果以每获得一个QALY的增量成本效果比(ICER)表示(1美元=65努尔特鲁姆)。
- 进行了单因素敏感性分析和概率敏感性分析以评估不确定性。
主要发现
- 与不接种相比,PCV10和PCV13分别获得0.0006和0.0007个QALY,人均终身额外成本分别为0.02美元和0.03美元。
- 与不接种相比,PCV10和PCV13的ICER分别为每QALY 36美元和40美元。
- PCV13与PCV10相比的ICER为每QALY 92美元。
- 一名卫生助理的全职等效(FTE)每年增加2.0,而其他卫生工作者的FTE每年可减少,尤其是专科医生(0.6-1.1 FTE)和护士(1-1.6 FTE)。
临床怎么用
- 作者建议将PCV10和PCV13纳入不丹的常规免疫规划。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Due to competing health priorities and limited resources, many low-income countries, even those with a high disease burden, are not able to introduce pneumococcal conjugate vaccines. OBJECTIVE: To determine the cost-utility of 10- and 13-valent pneumococcal conjugate vaccines (PCV10 and PCV13) compared to no vaccination in Bhutan. METHODS: A model-based cost-utility analysis was performed in the Bhutanese context using a government perspective. A Markov simulation model with one-year cycle length was used to estimate the costs and outcomes of three options: PCV10, PCV13 and no PCV programmes for a lifetime horizon. A discount rate of 3% per annum was applied. Results are presented using an incremental cost-effectiveness ratio (ICER) in United State Dollar per quality-adjusted life year (QALY) gained (USD 1 = Ngultrum 65). A one-way sensitivity analysis and a probabilistic sensitivity analysis were conducted to assess uncertainty. RESULTS: Compared to no vaccination, PCV10 and PCV13 gained 0.0006 and 0.0007 QALYs with additional lifetime costs of USD 0.02 and USD 0.03 per person, respectively. PCV10 and PCV13 generated ICERs of USD 36 and USD 40 per QALY gained compared to no vaccination. In addition, PCV13 produced an ICER of USD 92 compared with PCV10. When including PCV into the Expanded Programme on Immunization, the total 5-year budgetary requirement is anticipated to increase to USD. 3.77 million for PCV10 and USD 3.75 million for PCV13. Moreover, the full-time equivalent (FTE) of one health assistant would increase by 2.0 per year while the FTE of other health workers can be reduced each year, particularly of specialist (0.6-1.1 FTE) and nurse (1-1.6 FTE). CONCLUSION: At the suggested threshold of 1xGDP per capita equivalent to USD 2708, both PCVs are cost-effective in Bhutan and we recommend that they be included in the routine immunization programme.
引用
- Dorji K, Phuntsho S, Pempa, et al. Towards the introduction of pneumococcal conjugate vaccines in Bhutan: A cost-utility analysis to determine the optimal policy option. Vaccine. 2018. PMID: 29478752. doi:10.1016/j.vaccine.2018.02.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。